So, Joe, always a pleasure connecting in a more civilized hour. So apologies for changing as we were traveling. So I think first your question, just in terms of kind of planned regulatory interactions, I think what we're, again, right, this is still relatively hot off the press, very exciting data. I think we're fortunate to have already some of the top KOLs in the loop to begin with on the DFO study. and obviously an ongoing conversation with folks at the DAJ because they're a crucial partner. And so I think when we think about it, we're seeing basically a breakthrough win in DFO and targeting staff orders with SAGE, and that opens up multiple indications. I think specifically in DFOs, we think about next steps. We are gearing up to discuss with the regulatory agencies later this year. and again right this is an option for breakthrough designation and orphan designation so there's quite a few exciting levers that we can pull so that's now in the works and hopefully as we make progress we can update um but i think also some of the dialogue that we're having because people are excited because things should be working in a great unmet need and of course the navy sort of eyeing wound care, but basically going after staph aureus also opens up, you know, prosthetic joint infections, some skin infections, right? So there's a lot to think about. Again, we can't, you know, we don't want to bite more than we can chew. So I think first we're focusing on the DFO program and potentially

May 15, 2025 / receipt, needs a key / Joe Pangenis, other | earnings call 2025-05-15 | transcript 7edc1511-5f04-48c0-a34e-379babeb9452 | chars 11668-13167 | segment 11

The Board of Directors and executive management team were reconstituted, including the appointment of a new Chief Financial Officer effective February 27, 2026 and a new Chief Executive Officer effective March 4, 2026.

filing / Aug 19, 2026 / receipt

to as “householding,” potentially means extra convenience for stockholders and cost savings for companies. This year, several brokers with account holders who are our stockholders will be “householding” our proxy materials.

filing / Aug 11, 2026 / receipt

the unaudited pro forma condensed combined financial statements do not give effect to revenue synergies, operating efficiencies or cost

filing / Aug 11, 2026 / receipt

Michael Oster Chief Executive Officer

filing / Aug 11, 2026 / receipt